APA (7th ed.) Citation

Hamilton, E. P., Patel, M. R., Borges, V. F., Meisel, J. L., Okera, M., Alemany, C. A., . . . Lin, N. U. Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: Phase 1/2 study results. BMC.

Chicago Style (17th ed.) Citation

Hamilton, Erika P., et al. Palazestrant, a Novel Oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in Patients with ER+/HER2− advanced or Metastatic Breast Cancer: Phase 1/2 Study Results. BMC.

MLA (9th ed.) Citation

Hamilton, Erika P., et al. Palazestrant, a Novel Oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in Patients with ER+/HER2− advanced or Metastatic Breast Cancer: Phase 1/2 Study Results. BMC.